Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.

Lowery M, Shah MA, Smyth E, Epstein A, Segal A, Rosengarten O, Isacson R, Drukker L, Keinan A, Rachkiman M, Reissman P, Gabizon A, Kelsen D, O'Reilly EM.

J Gastrointest Cancer. 2011 Sep;42(3):160-4. doi: 10.1007/s12029-010-9197-1.

PMID:
20711688
2.

Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.

Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A.

Cancer Biol Ther. 2011 Aug 1;12(3):165-8. Epub 2011 Aug 1.

PMID:
21613821
3.

KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.

Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E.

Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2.

PMID:
21894049
5.

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.

Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'Reilly EM.

Oncologist. 2011;16(10):1397-402. doi: 10.1634/theoncologist.2011-0185. Epub 2011 Sep 20.

6.

BRCA and pancreatic cancer: selection of chemotherapy.

Kim R, Byer J, Saif MW.

JOP. 2012 Mar 10;13(2):180-1. Review.

7.

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.

Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW.

Br J Cancer. 2015 Jul 28;113(3):425-32. doi: 10.1038/bjc.2015.220. Epub 2015 Jul 16.

PMID:
26180923
8.

Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation.

Vyas O, Leung K, Ledbetter L, Kaley K, Rodriguez T, Garcon MC, Saif MW.

Anticancer Drugs. 2015 Feb;26(2):224-6. doi: 10.1097/CAD.0000000000000178.

PMID:
25304989
9.

PARP-inhibitors in BRCA-associated pancreatic cancer.

Bhalla A, Saif MW.

JOP. 2014 Jul 28;15(4):340-3. doi: 10.6092/1590-8577/2690.

10.

Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.

Ghiorzo P, Pensotti V, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bonelli L, Borgonovo G, Bruno W, Gozza A, Gargiulo S, Mastracci L, Nasti S, Palmieri G, Papadia F, Pastorino L, Russo A, Savarino V, Varesco L, Bernard L, Bianchi Scarrà G; Genoa Pancreatic Cancer Study Group.

Fam Cancer. 2012 Mar;11(1):41-7. doi: 10.1007/s10689-011-9483-5.

PMID:
21989927
11.

Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.

Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS.

Oncology. 2009;76(5):333-7. doi: 10.1159/000209962. Epub 2009 Mar 23.

PMID:
19307739
12.

[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].

Gong JF, Zhang XD, Li J, Di LJ, Jin ML, Shen L.

Ai Zheng. 2007 Aug;26(8):890-4. Chinese.

PMID:
17697554
14.

[Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].

Xie DR, Liang HL, Yang Q, Guo SS, Jiang ZM.

Ai Zheng. 2007 Aug;26(8):895-9. Chinese.

PMID:
17697555
15.

Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract.

Ritter PR, Tischoff I, Uhl W, Schmidt WE, Meier JJ.

Onkologie. 2010;33(11):617-9. doi: 10.1159/000321133. Epub 2010 Oct 19.

PMID:
20975309
16.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.

Invest New Drugs. 2005 Aug;23(4):369-75. Erratum in: Invest New Drugs. 2005 Dec;23(6):603. Kopteridis, Petros [corrected to Kopterides, Petros].

PMID:
16012797
17.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD.

J Clin Oncol. 2005 May 20;23(15):3509-16.

18.

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Wagner AD, Buechner-Steudel P, Wein A, Schmalenberg H, Lindig U, Moehler M, Behrens R, Kleber G, Kuss O, Fleig WE.

Ann Oncol. 2007 Jan;18(1):82-7. Epub 2006 Oct 9.

20.

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.

Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A.

J Clin Oncol. 2002 Mar 15;20(6):1512-8.

PMID:
11896099
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk